Article Sidebar
Published:
Feb 23, 2024Keywords:
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors Retain Copyright
Authors retain the copyright of the manuscript they have published in the Journal of the Pan African Thoracic Society. The Authors grant Scientific Scholar an exclusive license to publish the article and the article is made available under the terms of a Creative Commons Attribution-Non-Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0).
Open Access Publication and Creative Commons Licensing
Journal of the Pan African Thoracic Society is an open-access journal, and manuscripts published are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0), which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Compliance with Funder-Mandated Open Access Policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 License is able to meet that requirement through the available open-access license for approved funders.
Main Article Content
Trends of Xpert MTB/RIF in the diagnosis of Mycobacterium tuberculosis and rifampicin resistance in Southwest Nigeria: A 4-year retrospective study
Abstract
Objectives: In recent years, there has been an increased uptake of Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) for the diagnosis of tuberculosis (TB), with added benefits for detecting rifampicin-resistant TB (RR-TB). We set out to determine the trends in notification of MTB and RR-TB over 4 years in a tertiary hospital in Southwest Nigeria.
Materials and Methods: This is a retrospective analysis of single early morning sputum/gastric washing sample for presumed TB in a tertiary health center between January 2016 and December 2019. Xpert MTB/RIF was used to detect (MTB) and RR- TB.
Results: The mean age of the 4625 presumptive TB patients was 43.4 (18.8) years, with the majority aged 31–45 (30.6%). Males totaled 2247 (49.6%). Human immunodeficiency virus (HIV) coinfection was found in 756 (16.7%) of them. Using the Xpert MTB/RIF assay, the overall MTB notification was 12.9% (584/4526) and was associated with HIV status, P < 0.001. MTB notification trends increased from 5.6% in 2016 to 23.8% in 2019, P < 0.001. The overall yield of RR-TB was 7.5%. The proportion of RR-TB from TB cases declined from 28% in 2016 to 4.6% in 2019. Forty-two of the 44 cases of the RR-TB (42/572; 7.3%, [95% CI: 5.31, 9.75]) were new cases, with TB treatment failure and relapse cases accounting for 10.1% (2/11; 10.1%, [95% CI: 0.35, 42.5]) of all RR-TB cases (P < 0.01). RR-TB was associated with being older than 45 years (adjusted odds ratio = 2.046, [95% CI: 1.046, 4.004]). HIV infection status and gender had no effect on RR-TB status.
Conclusion: This study found an increase in MTB detection with Xpert MTB/RIF utilization. Ages >45 years have 2–4-fold increased risk of developing RR-TB and should be targeted for drug resistance prevention.
